Capvizr
THE DEAL, AT A GLANCE

Phil Rivers

From the announcement
01
MoleculesDrug research
Medicine development
What it doesPhil Rivers runs an AI-powered platform that aims to speed pharmaceutical innovation through computational medicine and data-driven drug discovery.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Who is involvedBacked by venture capital, private equity firmsFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03What happenedPhil Rivers raised $30M Series A, announced 2026-08-13From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
04Why it mattersPhil Rivers' $30M Series A is a mid-market Healthcare & Life Sciences capital-flow signal tied to renewed financing interest in China's AI biotech segment, rather than…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Phil Rivers · Financing Record

Explore source-linked visual explanations for Phil Rivers. Unsupported claims are withheld while source review continues.

Record 10242 · Recorded date: 2026-08-13

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime